SEC Form 4 · accession 0001439222-26-000077
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adams Catherine Owen
Director
Period of report
Jun 13, 2026
Accepted (ET)
Jun 16, 2026 · 4:09 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Jun 13, 2026 | M | 1,976 | $0.00 | A | 8,049 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted stock unitsF1,F2 | — | Jun 13, 2026 | M | 1,976 | D | — | — | Common stock | 1,976 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.